Hints and tips:
...Data from research group Recof also show domestic M&A is humming along nicely. More than 700 deals have been announced so far this year — roughly the same level as last year, when a record was set....
...firm Grand View Research....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...With a revised target date of 2018 for its initial submission to US regulators, it has fallen into third place behind Kite Pharma, a San Francisco-based biotech company, and Novartis, the Swiss drugmaker...
...The private equity veteran sits on the boards of four other listed companies, including Kite Pharma and Caesars Entertainment Corporation....
...Kite Pharma and Bluebird Bio fell 6 per cent in early trading....
...Other companies, including Kite Pharma of California and Novartis of Switzerland, have reported similar results....
...Shares in Kite Pharma, a rival group, fell almost 7 per cent on fears the FDA could take a broader look at the safety of Car-T and potentially suspend other studies, while Bluebird Bio dipped early before...
...But Juno Therapeutics and Kite Pharma of the US are hot on the heels of the Swiss company, with a host of others scrambling to catch up in a field that has attracted billions of dollars of investment....
...It is similar to high-profile therapies from Novartis of Switzerland and Juno Therapeutics and Kite Pharma of the US, which have attracted hundreds of millions of dollars of investment in the past two years...
...to research compiled by Morrison & Foerster, a law firm....
...Pfizer chief executive, is under pressure from shareholders to find an outlet for about $17bn in cash that it has trapped offshore out of the reach of the US taxman and to find new drugs to reinvigorate its research...
...Amgen, the big US biotech group, in January agreed an R&D collaboration worth up to $585m with Kite Pharma, a Californian company that, together with Seattle-based Juno Therapeutics, is vying with Novartis...
...Some critics argued that such deals destroyed value and disrupted research and development. What has changed?...
...In hot pursuit of Novartis are the US biotech companies Kite Pharma and Juno Therapeutics....
...It describes itself as a “conservative cornerstone” for an investor’s portfolio and boasts large defensive holdings in American Express and big pharma companies....
...(Financial Times) Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group....
...“Pharma companies will increasingly have to show payers [healthcare systems] demonstrable outcomes,” says Alun Wilcox, medical director at PDD, an innovation and design consultancy that works closely with...
...The injunction automatically preserves those gains, which feeds back to bolster research incentives....
International Edition